Ask AI
ProCE Banner Activity

Key Updates on Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma From ASH 2025

Clinical Thought

This commentary features expert insights into potentially practice-changing abstracts presented at ASH 2025 that highlight the evolving role of bispecific antibody (BsAb) therapy in MM, with an emphasis on how these data may inform treatment selection and sequencing in clinical practice.

Released: December 31, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Johnson & Johnson.

Johnson & Johnson

Target Audience

This activity is intended for oncologists, oncology nurses and nurse practitioners, physician assistants, pharmacists, and other healthcare professionals involved in caring for patients with multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate emerging safety and efficacy data on bispecific antibody therapeutics in the treatment of patients with multiple myeloma

Disclosure

Primary Author

Caitlin Costello, MD: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, Janssen, Kite; researcher: AstraZeneca, Bristol Myers Squibb, Janssen, Kite, Poseida, Takeda.

Jens Hillengass, MD, PhD: consultant/advisor/speaker: Janssen, Pfizer, Regeneron, Sebia, The Binding Site.